Ad-IFN-alpha (MD Anderson Cancer Center)

N/A

Report date: 2023/10/26 16:56:31

Base Information

Drug NameAd-IFN-alpha (MD Anderson Cancer Center)
Drug Alias Nameadenoviral-mediated IFN-alpha
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsUrinary Bladder Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Texas SystemNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Texas SystemNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsUrinary Bladder Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A